KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Gains from Investment Securities (2019 - 2025)

Boston Scientific's Gains from Investment Securities history spans 9 years, with the latest figure at $29.0 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 30.95% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $18.0 million, up 460.0%, while the annual FY2025 figure was $18.0 million, 28.0% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $29.0 million at Boston Scientific, up from -$11.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $58.0 million in Q4 2023 and bottomed at -$102.0 million in Q3 2022.
  • The 5-year median for Gains from Investment Securities is -$2.0 million (2021), against an average of -$750000.0.
  • The largest YoY upside for Gains from Investment Securities was 614.29% in 2025 against a maximum downside of 1900.0% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $35.0 million in 2021, then soared by 54.29% to $54.0 million in 2022, then increased by 7.41% to $58.0 million in 2023, then dropped by 27.59% to $42.0 million in 2024, then plummeted by 30.95% to $29.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Gains from Investment Securities are $29.0 million (Q4 2025), -$11.0 million (Q3 2025), and -$36.0 million (Q2 2025).